Kater, A. Et Al. 2020. Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis. LEUKEMIA & LYMPHOMA , vol.61 , 113-115.

Kater, A., Panagiotis, P., Aktan, M., ARSLAN, Ö., DEMİRKAN, F., Enggaard, L., ... Ferhanoglu, B.(2020). Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis. LEUKEMIA & LYMPHOMA , vol.61, 113-115.

Kater, Arnon Et Al. "Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis," LEUKEMIA & LYMPHOMA , vol.61, 113-115, 2020

Kater, Arnon Et Al. "Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis." LEUKEMIA & LYMPHOMA , vol.61, pp.113-115, 2020

Kater, A. Et Al. (2020) . "Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis." LEUKEMIA & LYMPHOMA , vol.61, pp.113-115.

@article{article, author={Arnon Kater Et Al. }, title={Minimal residual disease response with venetoclax monotherapy in relapsed/refractory CLL patients: VENICE I, phase 3b exploratory analysis}, journal={LEUKEMIA & LYMPHOMA}, year=2020, pages={113-115} }